A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer

NCT07283705 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Phase 2 Study
BMS-986504
MTAP-deleted Pancreatic Cancer

Interventions

DRUG: BMS-986504
DRUG: Gemcitabine
DRUG: Nab-paclitaxel
DRUG: mFOLFIRINOX

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]